| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
318,820 |
235,045 |
$22.73M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
105,207 |
95,061 |
$16.59M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
53,833 |
50,463 |
$14.09M |
| J9271 |
Injection, pembrolizumab, 1 mg |
825 |
625 |
$5.53M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
41,466 |
38,629 |
$4.65M |
| J1459 |
Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg |
3,064 |
938 |
$2.83M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
25,251 |
21,855 |
$2.61M |
| 77386 |
|
11,011 |
988 |
$2.57M |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
1,183 |
1,086 |
$2.46M |
| G0383 |
Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
15,027 |
14,403 |
$2.40M |
| G0382 |
Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
17,047 |
16,416 |
$2.15M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
11,967 |
7,788 |
$1.90M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
22,284 |
20,394 |
$1.82M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
12,414 |
11,798 |
$1.56M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
17,230 |
11,953 |
$1.50M |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
3,178 |
3,056 |
$1.46M |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
3,755 |
3,686 |
$1.40M |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
2,012 |
1,975 |
$1.26M |
| 71046 |
Radiologic examination, chest; 2 views |
30,809 |
28,608 |
$1.19M |
| 77412 |
|
10,407 |
1,187 |
$1.17M |
| G0381 |
Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
15,486 |
14,754 |
$1.15M |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
1,880 |
1,815 |
$1.15M |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
2,871 |
1,416 |
$1.10M |
| G0330 |
Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room |
467 |
460 |
$1.07M |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
216 |
207 |
$1.03M |
| Q9991 |
Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg |
625 |
556 |
$987K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
34,489 |
30,637 |
$981K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
5,032 |
4,513 |
$930K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
3,608 |
3,517 |
$921K |
| Q5121 |
Injection, infliximab-axxq, biosimilar, (avsola), 10 mg |
740 |
523 |
$921K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
22,128 |
18,454 |
$853K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
9,984 |
5,348 |
$838K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
7,943 |
6,507 |
$769K |
| G0008 |
Administration of influenza virus vaccine |
25,229 |
23,579 |
$744K |
| 90870 |
|
6,651 |
3,115 |
$739K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14,317 |
13,343 |
$733K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
22,111 |
16,650 |
$693K |
| 70450 |
Computed tomography, head or brain; without contrast material |
12,802 |
11,796 |
$679K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
994 |
980 |
$661K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
3,078 |
2,889 |
$658K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
6,113 |
3,543 |
$655K |
| 77334 |
|
1,909 |
1,471 |
$648K |
| J2350 |
Injection, ocrelizumab, 1 mg |
29 |
29 |
$644K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
30,666 |
27,565 |
$638K |
| 90832 |
Psychotherapy, 30 minutes with patient |
8,428 |
6,228 |
$631K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
16,457 |
13,600 |
$625K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
4,142 |
4,016 |
$605K |
| 90791 |
Psychiatric diagnostic evaluation |
7,379 |
6,636 |
$588K |
| Q9992 |
Injection, buprenorphine extended-release (sublocade), greater than 100 mg |
345 |
306 |
$585K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
3,758 |
3,606 |
$580K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
10,247 |
8,606 |
$580K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
9,761 |
8,488 |
$569K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
7,416 |
7,098 |
$557K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
996 |
963 |
$527K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
4,932 |
4,725 |
$498K |
| 90839 |
|
6,719 |
5,956 |
$487K |
| 70496 |
|
2,873 |
2,760 |
$479K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
6,466 |
5,974 |
$456K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
4,544 |
4,347 |
$423K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
6,845 |
5,823 |
$393K |
| J2426 |
Injection, paliperidone palmitate extended release (invega sustenna), 1 mg |
270 |
239 |
$377K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
6,536 |
6,342 |
$367K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
12,861 |
5,026 |
$362K |
| 54161 |
|
308 |
260 |
$361K |
| 36430 |
|
1,824 |
1,144 |
$358K |
| 77336 |
|
5,829 |
2,723 |
$340K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
77,969 |
65,940 |
$331K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
756 |
714 |
$322K |
| J2357 |
Injection, omalizumab, 5 mg |
529 |
170 |
$293K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
4,757 |
3,990 |
$291K |
| 76830 |
Ultrasound, transvaginal |
3,697 |
3,408 |
$283K |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
418 |
323 |
$274K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
18,734 |
14,656 |
$272K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
3,614 |
3,385 |
$267K |
| 93656 |
|
30 |
27 |
$259K |
| G0009 |
Administration of pneumococcal vaccine |
8,932 |
8,112 |
$255K |
| 90834 |
Psychotherapy, 45 minutes with patient |
3,081 |
2,362 |
$248K |
| 20610 |
|
2,239 |
1,790 |
$248K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
2,406 |
2,274 |
$243K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
7,102 |
4,578 |
$236K |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
327 |
265 |
$222K |
| 72141 |
|
1,765 |
1,669 |
$222K |
| 58571 |
|
40 |
38 |
$220K |
| 36902 |
|
316 |
287 |
$219K |
| 77300 |
|
1,396 |
1,358 |
$219K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
3,627 |
2,938 |
$218K |
| 71250 |
|
4,538 |
4,373 |
$217K |
| 76770 |
|
3,089 |
2,938 |
$210K |
| 93971 |
|
4,074 |
3,828 |
$208K |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
1,482 |
1,362 |
$200K |
| 90677 |
|
4,165 |
3,403 |
$197K |
| 96415 |
|
4,224 |
3,341 |
$196K |
| 99233 |
Prolong inpt eval add15 m |
3,896 |
2,804 |
$196K |
| 97803 |
|
9,144 |
8,613 |
$195K |
| 71045 |
Radiologic examination, chest; single view |
6,227 |
5,401 |
$194K |
| 10060 |
|
1,566 |
1,460 |
$191K |
| 78431 |
|
310 |
262 |
$186K |
| 70491 |
|
1,383 |
1,312 |
$185K |
| 93304 |
|
774 |
615 |
$184K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
705 |
636 |
$165K |
| 93308 |
|
1,549 |
1,429 |
$165K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
16,350 |
13,370 |
$160K |
| 95782 |
|
230 |
226 |
$158K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
938 |
713 |
$157K |
| 74174 |
|
1,361 |
1,313 |
$156K |
| 74183 |
|
966 |
940 |
$155K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
6,515 |
6,321 |
$150K |
| 95816 |
|
720 |
697 |
$147K |
| J0897 |
Injection, denosumab, 1 mg |
241 |
231 |
$146K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
2,371 |
1,837 |
$144K |
| 97802 |
|
3,334 |
3,148 |
$143K |
| J0741 |
Injection, cabotegravir and rilpivirine, 2mg/3mg |
48 |
38 |
$140K |
| 64642 |
|
502 |
385 |
$140K |
| 59025 |
Fetal non-stress test |
906 |
682 |
$140K |
| 76801 |
|
1,654 |
1,455 |
$138K |
| 47562 |
|
48 |
41 |
$131K |
| 64483 |
|
391 |
271 |
$130K |
| 90739 |
|
1,093 |
983 |
$130K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
13,915 |
4,699 |
$123K |
| 90686 |
|
17,038 |
15,936 |
$120K |
| 93458 |
|
123 |
118 |
$120K |
| 94060 |
|
797 |
724 |
$120K |
| 77290 |
|
824 |
792 |
$116K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
808 |
641 |
$116K |
| 77066 |
Tomosynthesis, mammo |
1,690 |
1,627 |
$115K |
| 64493 |
|
325 |
234 |
$114K |
| 67311 |
|
89 |
89 |
$114K |
| G0378 |
Hospital observation service, per hour |
11,440 |
9,944 |
$114K |
| 70486 |
|
1,111 |
1,066 |
$114K |
| 52356 |
|
64 |
51 |
$112K |
| 76642 |
|
2,469 |
2,370 |
$106K |
| 76536 |
|
2,061 |
1,963 |
$104K |
| 43235 |
|
297 |
281 |
$103K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
1,129 |
1,023 |
$100K |
| 59430 |
|
668 |
573 |
$97K |
| 64635 |
|
130 |
95 |
$96K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
3,302 |
1,681 |
$96K |
| 90480 |
|
4,571 |
3,722 |
$94K |
| 90651 |
|
4,450 |
3,849 |
$94K |
| 96417 |
|
2,425 |
1,636 |
$91K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
11,975 |
10,847 |
$91K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
11,984 |
10,855 |
$91K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
206 |
136 |
$90K |
| 62323 |
|
336 |
241 |
$89K |
| 64615 |
|
738 |
518 |
$89K |
| 95819 |
|
397 |
383 |
$84K |
| 86900 |
|
10,923 |
9,796 |
$82K |
| 97162 |
|
4,150 |
3,907 |
$81K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
59,794 |
50,347 |
$81K |
| 27130 |
|
15 |
12 |
$80K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
1,000 |
975 |
$77K |
| 96409 |
|
598 |
453 |
$77K |
| 96367 |
|
2,262 |
1,710 |
$77K |
| 93970 |
|
761 |
708 |
$75K |
| 99188 |
|
3,476 |
2,968 |
$74K |
| 75561 |
|
233 |
230 |
$70K |
| Q5108 |
Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg |
53 |
39 |
$69K |
| J0185 |
Injection, aprepitant, 1 mg |
503 |
294 |
$68K |
| 72197 |
|
264 |
253 |
$66K |
| 77295 |
|
154 |
145 |
$65K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
843 |
650 |
$64K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
3,240 |
2,606 |
$63K |
| 77065 |
Tomosynthesis, mammo |
1,196 |
1,126 |
$63K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,888 |
2,536 |
$63K |
| 91320 |
|
1,770 |
1,378 |
$63K |
| 74230 |
|
727 |
710 |
$61K |
| Q3014 |
Telehealth originating site facility fee |
4,802 |
4,021 |
$60K |
| 72100 |
|
3,440 |
3,280 |
$59K |
| 93798 |
|
980 |
183 |
$59K |
| 97166 |
|
2,863 |
2,739 |
$58K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
3,558 |
2,278 |
$58K |
| 92587 |
|
274 |
218 |
$57K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
2,017 |
1,763 |
$57K |
| 97161 |
|
1,741 |
1,399 |
$56K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
6,432 |
5,025 |
$56K |
| 93880 |
|
754 |
708 |
$54K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
769 |
758 |
$53K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
2,456 |
2,367 |
$52K |
| 99222 |
Initial hospital care, per day, moderate complexity |
826 |
800 |
$52K |
| 80061 |
Lipid panel |
7,618 |
6,572 |
$52K |
| Q5107 |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
44 |
25 |
$50K |
| 93303 |
Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study |
195 |
166 |
$49K |
| 76825 |
|
158 |
111 |
$49K |
| 77301 |
|
101 |
93 |
$48K |
| 80053 |
Comprehensive metabolic panel |
85,997 |
70,081 |
$48K |
| 72158 |
|
386 |
360 |
$48K |
| 96411 |
|
1,160 |
801 |
$48K |
| 94010 |
|
1,910 |
1,785 |
$47K |
| C8930 |
Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision |
174 |
134 |
$47K |
| 27447 |
|
19 |
16 |
$47K |
| 99402 |
|
1,886 |
1,447 |
$47K |
| 91322 |
|
1,062 |
951 |
$46K |
| 96158 |
|
1,214 |
1,042 |
$46K |
| 29581 |
|
666 |
309 |
$46K |
| 58301 |
|
239 |
178 |
$45K |
| G0379 |
Direct admission of patient for hospital observation care |
41 |
41 |
$45K |
| 31575 |
|
409 |
310 |
$44K |
| 99215 |
Prolong outpt/office vis |
570 |
535 |
$43K |
| 20611 |
|
420 |
281 |
$43K |
| 93296 |
|
2,705 |
2,178 |
$42K |
| 95811 |
|
67 |
65 |
$40K |
| 74018 |
|
3,086 |
2,715 |
$40K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
391 |
325 |
$40K |
| 19083 |
|
37 |
36 |
$39K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
92,474 |
75,551 |
$39K |
| J1610 |
Injection, glucagon hydrochloride, per 1 mg |
587 |
567 |
$38K |
| G0390 |
Trauma response team associated with hospital critical care service |
87 |
85 |
$37K |
| 73221 |
|
247 |
202 |
$37K |
| 71271 |
|
662 |
636 |
$36K |
| 77470 |
|
184 |
181 |
$36K |
| 42830 |
|
15 |
15 |
$34K |
| 92557 |
|
1,984 |
1,876 |
$34K |
| 90670 |
|
4,154 |
4,097 |
$33K |
| 84443 |
Thyroid stimulating hormone (TSH) |
11,300 |
10,112 |
$33K |
| J9305 |
Injection, pemetrexed, not otherwise specified, 10 mg |
73 |
38 |
$32K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
5,919 |
5,547 |
$31K |
| 90656 |
|
5,470 |
4,962 |
$31K |
| 87481 |
|
9,921 |
4,739 |
$31K |
| 73030 |
|
5,058 |
4,398 |
$30K |
| 94726 |
|
507 |
486 |
$30K |
| 73562 |
|
2,866 |
2,601 |
$29K |
| 93017 |
|
1,829 |
1,656 |
$29K |
| 73502 |
|
4,718 |
4,438 |
$28K |
| 92579 |
|
891 |
794 |
$28K |
| 99381 |
|
451 |
422 |
$28K |
| 86780 |
|
2,708 |
2,446 |
$28K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
3,707 |
3,262 |
$27K |
| 52000 |
|
158 |
117 |
$27K |
| 76870 |
|
907 |
856 |
$26K |
| 74178 |
|
157 |
147 |
$26K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
5,692 |
1,711 |
$26K |
| 76885 |
|
366 |
350 |
$25K |
| 58300 |
|
651 |
556 |
$25K |
| 90847 |
Family psychotherapy with the patient present, 50 minutes |
208 |
142 |
$25K |
| 90678 |
|
90 |
85 |
$25K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
9,220 |
7,945 |
$25K |
| 73630 |
|
4,938 |
4,314 |
$25K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
7,653 |
6,866 |
$24K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
3,745 |
3,356 |
$24K |
| 76882 |
|
1,445 |
1,333 |
$24K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
9,150 |
3,242 |
$24K |
| 99221 |
|
548 |
526 |
$24K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
3,203 |
2,775 |
$23K |
| 77280 |
|
391 |
357 |
$23K |
| 72146 |
|
301 |
266 |
$23K |
| 97167 |
|
1,569 |
1,498 |
$22K |
| J1437 |
Injection, ferric derisomaltose, 10 mg |
13 |
12 |
$22K |
| J0485 |
Injection, belatacept, 1 mg |
54 |
24 |
$22K |
| 73564 |
|
3,902 |
3,579 |
$22K |
| 99401 |
|
1,705 |
1,127 |
$22K |
| 99223 |
Prolong inpt eval add15 m |
221 |
216 |
$22K |
| 92611 |
|
509 |
500 |
$22K |
| 90732 |
|
698 |
691 |
$21K |
| 62321 |
|
92 |
62 |
$21K |
| 36415 |
Collection of venous blood by venipuncture |
46,797 |
35,800 |
$21K |
| 20680 |
|
13 |
12 |
$21K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
16,506 |
14,705 |
$20K |
| 17110 |
|
424 |
289 |
$19K |
| 0124A |
|
1,078 |
1,062 |
$19K |
| 97163 |
|
1,176 |
1,105 |
$19K |
| 90734 |
|
1,804 |
1,756 |
$19K |
| 29405 |
|
128 |
87 |
$18K |
| 70498 |
|
2,809 |
2,699 |
$18K |
| 11102 |
|
340 |
240 |
$18K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
2,580 |
2,473 |
$18K |
| 80305 |
|
8,121 |
5,288 |
$17K |
| 93923 |
|
300 |
263 |
$17K |
| G0498 |
Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion |
91 |
66 |
$17K |
| 93797 |
|
300 |
44 |
$17K |
| 99406 |
|
2,784 |
2,655 |
$17K |
| 73610 |
|
4,381 |
3,916 |
$17K |
| 72040 |
|
1,567 |
1,490 |
$16K |
| 20550 |
|
104 |
82 |
$16K |
| 90662 |
|
2,124 |
2,064 |
$16K |
| D0145 |
Oral evaluation for a patient under three years of age |
879 |
851 |
$16K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
27,439 |
18,758 |
$16K |
| 87511 |
|
5,355 |
4,745 |
$16K |
| 52332 |
|
13 |
12 |
$15K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
5,425 |
4,801 |
$15K |
| 36591 |
|
2,452 |
1,509 |
$15K |
| 97165 |
|
566 |
500 |
$15K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
1,661 |
554 |
$15K |
| 93456 |
|
12 |
12 |
$14K |
| 94664 |
|
262 |
204 |
$14K |
| 64633 |
|
19 |
12 |
$14K |
| 43249 |
|
27 |
26 |
$14K |
| 90619 |
|
1,510 |
1,102 |
$14K |
| 72082 |
|
828 |
748 |
$14K |
| 95700 |
|
103 |
97 |
$14K |
| 99385 |
|
195 |
160 |
$14K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
26,094 |
22,103 |
$14K |
| 73110 |
|
3,590 |
3,045 |
$14K |
| 92610 |
|
593 |
559 |
$13K |
| 43264 |
|
12 |
12 |
$13K |
| D1206 |
Topical application of fluoride varnish |
1,091 |
1,067 |
$13K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
3,715 |
3,374 |
$13K |
| 73130 |
|
2,850 |
2,480 |
$13K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
682 |
659 |
$13K |
| 72070 |
|
695 |
667 |
$13K |
| 29075 |
|
71 |
52 |
$13K |
| 90837 |
Psychotherapy, 53 minutes with patient |
139 |
101 |
$13K |
| 87522 |
Neg quan hep c or qual rna |
1,006 |
896 |
$12K |
| 77080 |
|
246 |
191 |
$12K |
| 0001A |
|
387 |
372 |
$12K |
| 17250 |
|
147 |
91 |
$12K |
| 0054A |
|
551 |
540 |
$12K |
| 93975 |
|
79 |
73 |
$11K |
| 87536 |
|
500 |
488 |
$11K |
| 77338 |
|
88 |
81 |
$11K |
| 90746 |
|
458 |
402 |
$11K |
| 88142 |
|
2,260 |
2,211 |
$11K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
7,632 |
5,789 |
$11K |
| G0260 |
Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography |
39 |
32 |
$11K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
13,062 |
12,063 |
$10K |
| 73590 |
|
1,784 |
1,560 |
$10K |
| 99495 |
|
130 |
113 |
$10K |
| 82728 |
|
3,979 |
3,466 |
$10K |
| 77072 |
|
161 |
157 |
$10K |
| 96127 |
|
1,563 |
1,340 |
$9K |
| 96401 |
|
413 |
274 |
$9K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
1,075 |
869 |
$9K |
| G0384 |
Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
43 |
43 |
$9K |
| P9040 |
Red blood cells, leukocytes reduced, irradiated, each unit |
48 |
28 |
$9K |
| 95714 |
|
15 |
13 |
$9K |
| C1769 |
Guide wire |
7,236 |
6,799 |
$9K |
| 83655 |
|
3,090 |
2,670 |
$9K |
| 73560 |
|
1,443 |
1,289 |
$9K |
| 86870 |
|
65 |
53 |
$8K |
| 85027 |
|
21,567 |
14,961 |
$8K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
26 |
24 |
$8K |
| 96152 |
|
141 |
134 |
$8K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
420 |
321 |
$8K |
| 73552 |
|
1,445 |
1,279 |
$8K |
| 82607 |
|
3,093 |
2,782 |
$8K |
| J2704 |
Injection, propofol, 10 mg |
44,655 |
37,109 |
$8K |
| 99403 |
|
168 |
123 |
$8K |
| 86480 |
|
382 |
305 |
$8K |
| 92582 |
|
154 |
126 |
$8K |
| 99383 |
|
120 |
96 |
$8K |
| 76881 |
|
121 |
95 |
$8K |
| 0002A |
|
223 |
220 |
$8K |
| 90716 |
|
2,492 |
2,212 |
$8K |
| 99407 |
|
742 |
711 |
$8K |
| 99404 |
|
127 |
91 |
$7K |
| 75574 |
|
82 |
82 |
$7K |
| 88342 |
|
3,618 |
3,354 |
$7K |
| 93242 |
|
615 |
494 |
$7K |
| 95911 |
|
15 |
15 |
$7K |
| 81025 |
|
8,920 |
8,039 |
$7K |
| C8908 |
Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral |
26 |
26 |
$7K |
| 29065 |
|
34 |
25 |
$7K |
| 99205 |
Prolong outpt/office vis |
68 |
68 |
$7K |
| 76604 |
|
494 |
473 |
$7K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
15,537 |
13,805 |
$7K |
| 92552 |
|
167 |
153 |
$6K |
| 85610 |
|
13,478 |
9,577 |
$6K |
| 95909 |
|
65 |
37 |
$6K |
| 82746 |
|
2,416 |
2,183 |
$6K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
244 |
90 |
$6K |
| 86803 |
|
2,533 |
2,208 |
$6K |
| 76775 |
|
633 |
612 |
$6K |
| 72170 |
|
1,003 |
866 |
$6K |
| 86481 |
|
180 |
175 |
$6K |
| 11981 |
|
94 |
69 |
$6K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
5,192 |
2,971 |
$6K |
| 97116 |
|
3,098 |
1,669 |
$6K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
239 |
228 |
$6K |
| 84702 |
|
3,401 |
2,799 |
$6K |
| 12001 |
|
1,079 |
1,029 |
$6K |
| 93225 |
|
214 |
182 |
$5K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
121 |
109 |
$5K |
| 88184 |
|
80 |
65 |
$5K |
| 11104 |
|
48 |
34 |
$5K |
| 90673 |
|
78 |
66 |
$5K |
| 86706 |
|
1,634 |
1,471 |
$5K |
| 69210 |
|
318 |
243 |
$5K |
| 97535 |
Self-care/home management training, each 15 minutes |
3,048 |
1,906 |
$5K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
13 |
13 |
$5K |
| 73140 |
|
1,387 |
1,215 |
$5K |
| D1208 |
Topical application of fluoride, excluding varnish |
410 |
409 |
$5K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
5,109 |
4,237 |
$5K |
| G0010 |
Administration of hepatitis b vaccine |
251 |
237 |
$5K |
| 83735 |
|
17,743 |
12,131 |
$5K |
| 57454 |
|
15 |
15 |
$5K |
| 96150 |
|
79 |
76 |
$5K |
| 93298 |
|
210 |
151 |
$5K |
| 83550 |
|
3,132 |
2,715 |
$5K |
| J1750 |
Injection, iron dextran, 50 mg |
17 |
17 |
$5K |
| 72156 |
|
14 |
14 |
$4K |
| 70544 |
|
42 |
38 |
$4K |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
1,932 |
1,833 |
$4K |
| 86704 |
|
1,331 |
1,209 |
$4K |
| 73521 |
|
229 |
212 |
$4K |
| 58100 |
|
42 |
33 |
$4K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
57 |
57 |
$4K |
| 87340 |
|
2,659 |
2,446 |
$4K |
| 74240 |
|
29 |
25 |
$4K |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
2,418 |
2,253 |
$4K |
| 93246 |
|
393 |
321 |
$4K |
| 73080 |
|
1,172 |
1,059 |
$4K |
| 30140 |
|
20 |
13 |
$4K |
| 82950 |
|
896 |
846 |
$4K |
| 72131 |
|
149 |
134 |
$4K |
| 0081A |
|
147 |
147 |
$4K |
| 96156 |
|
74 |
71 |
$4K |
| 86850 |
|
10,860 |
9,838 |
$4K |
| 83970 |
|
387 |
325 |
$4K |
| 96402 |
|
256 |
223 |
$4K |
| 83540 |
|
3,299 |
2,849 |
$4K |
| 84439 |
|
1,842 |
1,615 |
$4K |
| 93922 |
|
548 |
499 |
$4K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
4,349 |
4,122 |
$4K |
| 0072A |
|
186 |
179 |
$4K |
| 64400 |
|
23 |
16 |
$4K |
| 51700 |
|
57 |
24 |
$3K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
4,016 |
3,791 |
$3K |
| G0101 |
Cervical or vaginal cancer screening; pelvic and clinical breast examination |
67 |
67 |
$3K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
43,385 |
34,793 |
$3K |
| 73070 |
|
592 |
496 |
$3K |
| 69209 |
|
274 |
225 |
$3K |
| 95910 |
|
16 |
14 |
$3K |
| 72081 |
|
129 |
107 |
$3K |
| 73700 |
|
55 |
50 |
$3K |
| G0399 |
Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation |
32 |
28 |
$3K |
| G0297 |
Low dose ct scan (ldct) for lung cancer screening |
120 |
120 |
$3K |
| 11982 |
|
15 |
12 |
$3K |
| 90473 |
|
132 |
112 |
$3K |
| 17311 |
|
16 |
13 |
$3K |
| 88341 |
|
2,152 |
1,909 |
$3K |
| 84703 |
|
15,085 |
14,009 |
$3K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
63 |
63 |
$3K |
| 96523 |
|
146 |
124 |
$3K |
| 87070 |
|
11,788 |
10,757 |
$3K |
| 96376 |
|
5,529 |
4,565 |
$3K |
| 0052A |
|
86 |
86 |
$3K |
| 92652 |
|
20 |
12 |
$3K |
| 88307 |
|
2,514 |
2,413 |
$3K |
| 86003 |
|
106 |
81 |
$3K |
| 73600 |
|
766 |
674 |
$3K |
| 87186 |
|
6,206 |
5,568 |
$3K |
| J1756 |
Injection, iron sucrose, 1 mg |
3,450 |
1,475 |
$3K |
| 0082A |
|
86 |
86 |
$3K |
| 97760 |
|
448 |
393 |
$3K |
| 86787 |
|
652 |
603 |
$3K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
16 |
16 |
$3K |
| 93926 |
|
104 |
88 |
$3K |
| 0071A |
|
167 |
162 |
$3K |
| 86901 |
|
11,110 |
9,977 |
$3K |
| 81001 |
|
18,358 |
16,483 |
$3K |
| 83880 |
|
5,965 |
5,395 |
$3K |
| 84403 |
|
233 |
166 |
$3K |
| 86923 |
|
829 |
610 |
$2K |
| 73090 |
|
866 |
740 |
$2K |
| 83021 |
|
361 |
356 |
$2K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
336 |
265 |
$2K |
| J1644 |
Injection, heparin sodium, per 1000 units |
18,712 |
8,922 |
$2K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
17,097 |
13,359 |
$2K |
| 86140 |
|
7,691 |
6,681 |
$2K |
| 96381 |
|
174 |
163 |
$2K |
| 72110 |
|
144 |
127 |
$2K |
| 87077 |
|
7,360 |
6,629 |
$2K |
| 31231 |
|
23 |
17 |
$2K |
| 83690 |
|
17,025 |
15,309 |
$2K |
| 90715 |
|
9,305 |
8,569 |
$2K |
| 98929 |
|
128 |
114 |
$2K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
2,147 |
2,101 |
$2K |
| 84484 |
|
23,568 |
14,131 |
$2K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
1,802 |
1,613 |
$2K |
| M0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring |
73 |
71 |
$2K |
| 76981 |
|
24 |
24 |
$2K |
| 77387 |
|
163 |
24 |
$2K |
| 0004A |
|
657 |
650 |
$2K |
| 87517 |
|
96 |
94 |
$2K |
| 90688 |
|
405 |
387 |
$2K |
| 82947 |
|
663 |
580 |
$2K |
| 99234 |
|
52 |
12 |
$2K |
| 90620 |
|
47 |
39 |
$2K |
| Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
22 |
13 |
$2K |
| 80178 |
|
1,016 |
900 |
$2K |
| 64447 |
|
186 |
176 |
$2K |
| 96112 |
|
20 |
14 |
$2K |
| 0051A |
|
58 |
54 |
$2K |
| 80076 |
|
904 |
784 |
$2K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
24,750 |
22,890 |
$2K |
| 76376 |
|
2,130 |
1,835 |
$2K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
4,424 |
3,729 |
$2K |
| J7325 |
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg |
59 |
39 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
42,125 |
37,348 |
$2K |
| 72157 |
|
27 |
25 |
$2K |
| S9441 |
Asthma education, non-physician provider, per session |
167 |
122 |
$2K |
| D0330 |
Panoramic radiographic image |
49 |
48 |
$2K |
| 81003 |
|
22,088 |
18,556 |
$2K |
| 11900 |
|
50 |
36 |
$2K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
381 |
365 |
$2K |
| 87468 |
|
733 |
641 |
$2K |
| 93356 |
|
1,631 |
1,369 |
$2K |
| 87469 |
|
732 |
641 |
$2K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
21,279 |
12,965 |
$2K |
| 82043 |
|
2,373 |
2,128 |
$1K |
| C1776 |
Joint device (implantable) |
475 |
450 |
$1K |
| C1726 |
Catheter, balloon dilatation, non-vascular |
1,380 |
1,335 |
$1K |
| 00170 |
Anesthesia for intraoral procedures, including biopsy |
13 |
13 |
$1K |
| 87040 |
|
5,048 |
4,211 |
$1K |
| 98928 |
|
364 |
243 |
$1K |
| 82784 |
|
533 |
388 |
$1K |
| C1729 |
Catheter, drainage |
453 |
415 |
$1K |
| 86618 |
|
1,246 |
1,126 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
31,945 |
28,739 |
$1K |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
58 |
36 |
$1K |
| 93312 |
|
15 |
14 |
$1K |
| 92551 |
|
169 |
160 |
$1K |
| 81000 |
|
5,501 |
5,210 |
$1K |
| 29515 |
|
13 |
13 |
$1K |
| 84402 |
|
128 |
88 |
$1K |
| 64415 |
|
105 |
94 |
$1K |
| 73000 |
|
138 |
115 |
$1K |
| 99386 |
|
17 |
13 |
$1K |
| 73060 |
|
304 |
244 |
$1K |
| 74221 |
|
18 |
15 |
$1K |
| 90681 |
|
3,921 |
3,554 |
$1K |
| 77332 |
|
28 |
26 |
$1K |
| 93280 |
|
65 |
57 |
$1K |
| 72050 |
|
18 |
12 |
$1K |
| 92201 |
|
83 |
57 |
$1K |
| 86902 |
|
13 |
13 |
$1K |
| 51702 |
|
78 |
64 |
$1K |
| 71101 |
|
82 |
67 |
$1K |
| 85730 |
|
3,863 |
2,682 |
$1K |
| 84425 |
|
127 |
93 |
$1K |
| J1815 |
Injection, insulin, per 5 units |
7,160 |
3,919 |
$1K |
| 74220 |
|
16 |
16 |
$1K |
| 12002 |
|
330 |
309 |
$1K |
| 85018 |
|
2,613 |
2,172 |
$1K |
| 76641 |
|
13 |
12 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
25 |
25 |
$1K |
| 51798 |
|
1,189 |
901 |
$1K |
| 92553 |
|
35 |
27 |
$998.72 |
| 96154 |
|
80 |
76 |
$972.93 |
| 83993 |
|
105 |
79 |
$964.98 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
5,621 |
3,595 |
$955.53 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
1,578 |
1,491 |
$954.63 |
| 80074 |
|
184 |
155 |
$946.63 |
| G0328 |
Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous |
126 |
124 |
$943.50 |
| 99460 |
|
15 |
15 |
$941.95 |
| 80164 |
|
484 |
429 |
$941.67 |
| 99382 |
|
15 |
12 |
$935.64 |
| 82670 |
|
80 |
55 |
$927.39 |
| 84100 |
|
3,914 |
2,329 |
$926.51 |
| 0031A |
|
33 |
33 |
$925.16 |
| 88112 |
|
595 |
522 |
$907.45 |
| 95800 |
|
12 |
12 |
$889.37 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
5,020 |
2,894 |
$882.47 |
| 86360 |
|
156 |
152 |
$878.03 |
| 73100 |
|
144 |
81 |
$874.52 |
| 98926 |
|
312 |
197 |
$869.35 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
4,251 |
3,289 |
$868.68 |
| 90658 |
|
44 |
44 |
$855.66 |
| 74330 |
|
424 |
407 |
$852.38 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
5,347 |
4,734 |
$828.24 |
| 99384 |
|
13 |
13 |
$819.09 |
| 88304 |
|
2,435 |
2,364 |
$810.18 |
| C9399 |
Unclassified drugs or biologicals |
1,185 |
1,132 |
$809.93 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
7,358 |
6,205 |
$780.44 |
| 82570 |
|
1,626 |
1,426 |
$778.73 |
| 84460 |
|
521 |
495 |
$778.66 |
| 99397 |
|
41 |
29 |
$774.56 |
| 85660 |
|
398 |
388 |
$772.18 |
| 92567 |
|
4,147 |
3,880 |
$769.15 |
| 99173 |
|
399 |
365 |
$766.12 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
2,369 |
2,171 |
$757.79 |
| 80069 |
|
241 |
213 |
$731.27 |
| 76000 |
|
122 |
121 |
$722.67 |
| 86359 |
|
156 |
152 |
$722.60 |
| 83001 |
|
112 |
84 |
$712.55 |
| 90710 |
|
1,605 |
1,342 |
$701.00 |
| 84153 |
|
142 |
121 |
$693.18 |
| 0154A |
|
54 |
54 |
$692.30 |
| 86762 |
|
892 |
803 |
$687.39 |
| C2617 |
Stent, non-coronary, temporary, without delivery system |
1,236 |
1,157 |
$682.15 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
20,012 |
17,132 |
$666.87 |
| 70355 |
|
138 |
129 |
$666.07 |
| 83605 |
|
5,747 |
4,721 |
$663.00 |
| 93750 |
|
13 |
12 |
$661.17 |
| 85652 |
|
3,128 |
2,691 |
$656.30 |
| 86364 |
|
225 |
166 |
$649.35 |
| 0003A |
|
54 |
54 |
$642.66 |
| 12011 |
|
439 |
414 |
$640.78 |
| 87081 |
|
6,366 |
5,127 |
$640.52 |
| 82805 |
|
2,456 |
1,913 |
$639.04 |
| 29125 |
|
190 |
178 |
$626.30 |
| 81002 |
|
11,499 |
9,521 |
$624.64 |
| C8928 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report |
14 |
14 |
$618.33 |
| 17000 |
|
160 |
126 |
$614.50 |
| 76937 |
|
879 |
813 |
$603.81 |
| 98925 |
|
184 |
98 |
$598.91 |
| 73620 |
|
74 |
54 |
$590.30 |
| 87205 |
|
4,341 |
3,888 |
$585.71 |
| 86334 |
|
124 |
102 |
$580.45 |
| 84146 |
|
66 |
47 |
$571.54 |
| 83037 |
|
3,326 |
3,280 |
$514.92 |
| 86038 |
|
147 |
113 |
$500.06 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
132 |
119 |
$498.31 |
| 85379 |
|
3,464 |
3,277 |
$495.83 |
| 84156 |
|
1,366 |
1,178 |
$495.75 |
| 90380 |
|
37 |
31 |
$494.55 |
| J2359 |
Injection, olanzapine, 0.5 mg |
23 |
14 |
$485.68 |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
36 |
36 |
$484.44 |
| 90744 |
|
2,036 |
1,933 |
$483.20 |
| 70360 |
|
26 |
25 |
$472.90 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
562 |
373 |
$451.73 |
| 82550 |
|
2,279 |
1,913 |
$445.99 |
| 99443 |
|
19 |
16 |
$430.80 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
4,007 |
2,115 |
$413.49 |
| 93325 |
|
2,266 |
1,942 |
$395.23 |
| 92555 |
|
323 |
283 |
$386.53 |
| 97810 |
|
180 |
165 |
$381.99 |
| 83615 |
|
1,100 |
758 |
$377.56 |
| 83921 |
|
115 |
115 |
$377.17 |
| 95970 |
|
81 |
56 |
$366.01 |
| A4648 |
Tissue marker, implantable, any type, each |
252 |
238 |
$364.03 |
| J2785 |
Injection, regadenoson, 0.1 mg |
927 |
829 |
$357.80 |
| 82948 |
|
5,309 |
1,962 |
$355.96 |
| 92550 |
|
58 |
53 |
$354.71 |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
17 |
12 |
$333.89 |
| 72190 |
|
14 |
13 |
$326.83 |
| 72020 |
|
178 |
164 |
$326.68 |
| C1732 |
Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping |
46 |
42 |
$316.54 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
7,087 |
6,372 |
$314.36 |
| 87209 |
|
55 |
37 |
$312.80 |
| J3480 |
Injection, potassium chloride, per 2 meq |
3,447 |
1,792 |
$307.95 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
1,958 |
1,517 |
$307.74 |
| 36600 |
|
47 |
39 |
$307.45 |
| 85045 |
|
836 |
625 |
$307.30 |
| 76942 |
|
836 |
749 |
$298.68 |
| C1758 |
Catheter, ureteral |
1,692 |
1,582 |
$297.78 |
| 72192 |
|
15 |
14 |
$294.21 |
| 83020 |
|
152 |
114 |
$283.14 |
| 84165 |
|
123 |
101 |
$279.08 |
| 87206 |
|
711 |
521 |
$278.48 |
| 82248 |
|
203 |
157 |
$277.25 |
| 96167 |
|
34 |
29 |
$276.66 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
6,001 |
4,167 |
$275.65 |
| 73565 |
|
23 |
14 |
$274.51 |
| 98927 |
|
67 |
49 |
$267.92 |
| 82533 |
|
46 |
34 |
$263.20 |
| 80197 |
|
145 |
108 |
$263.03 |
| 82785 |
|
50 |
38 |
$256.83 |
| 86708 |
|
52 |
51 |
$251.26 |
| 91200 |
|
17 |
12 |
$249.68 |
| 97014 |
|
237 |
86 |
$249.41 |
| 46600 |
|
92 |
71 |
$240.93 |
| 73660 |
|
87 |
75 |
$234.11 |
| J1630 |
Injection, haloperidol, up to 5 mg |
4,209 |
3,744 |
$231.48 |
| C1730 |
Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) |
67 |
60 |
$216.80 |
| 87505 |
|
39 |
27 |
$216.51 |
| 85651 |
|
1,025 |
947 |
$209.51 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
5,523 |
1,660 |
$202.14 |
| 85007 |
|
1,412 |
1,271 |
$197.13 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
1,191 |
965 |
$190.86 |
| P9612 |
Catheterization for collection of specimen, single patient, all places of service |
189 |
161 |
$189.28 |
| 87529 |
|
153 |
69 |
$186.34 |
| J2060 |
Injection, lorazepam, 2 mg |
5,376 |
4,064 |
$182.51 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
440 |
180 |
$182.27 |
| 87634 |
|
145 |
144 |
$181.98 |
| 96040 |
|
12 |
12 |
$181.74 |
| C1727 |
Catheter, balloon tissue dissector, non-vascular (insertable) |
466 |
446 |
$181.16 |
| J2720 |
Injection, protamine sulfate, per 10 mg |
187 |
178 |
$178.18 |
| 82105 |
|
54 |
43 |
$174.44 |
| 93613 |
|
14 |
13 |
$172.66 |
| 87210 |
|
1,642 |
1,390 |
$171.76 |
| 96165 |
|
26 |
15 |
$163.71 |
| G0296 |
Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) |
13 |
13 |
$163.08 |
| 86431 |
|
117 |
88 |
$161.02 |
| J1790 |
Injection, droperidol, up to 5 mg |
4,227 |
3,619 |
$159.42 |
| 87177 |
|
55 |
37 |
$154.31 |
| 77073 |
|
66 |
50 |
$153.22 |
| 83002 |
|
20 |
12 |
$148.16 |
| 99152 |
|
1,658 |
1,605 |
$143.44 |
| 83521 |
|
50 |
39 |
$138.25 |
| 94729 |
|
1,055 |
1,015 |
$134.99 |
| 88173 |
|
123 |
100 |
$133.16 |
| 96164 |
|
26 |
15 |
$130.15 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
275 |
196 |
$129.46 |
| A9555 |
Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries |
328 |
277 |
$127.92 |
| 82330 |
|
50 |
39 |
$124.54 |
| 82140 |
|
254 |
224 |
$121.22 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
2,313 |
786 |
$120.46 |
| 77417 |
|
367 |
199 |
$117.92 |
| 83721 |
|
53 |
45 |
$116.78 |
| 87075 |
|
990 |
899 |
$113.98 |
| 84550 |
|
297 |
196 |
$112.47 |
| 84450 |
|
88 |
88 |
$110.59 |
| 86682 |
|
14 |
12 |
$109.78 |
| 82977 |
|
48 |
42 |
$109.60 |
| 88313 |
|
187 |
175 |
$108.51 |
| 87493 |
|
26 |
26 |
$104.48 |
| 84134 |
|
44 |
40 |
$102.13 |
| 84132 |
|
814 |
698 |
$101.54 |
| J9045 |
Injection, carboplatin, 50 mg |
1,311 |
930 |
$101.46 |
| J1920 |
Injection, labetalol hydrochloride, 5 mg |
203 |
176 |
$100.07 |
| 87102 |
|
279 |
224 |
$97.53 |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
2,388 |
2,067 |
$97.50 |
| 90691 |
|
779 |
761 |
$95.83 |
| J3490 |
Unclassified drugs |
5,025 |
4,492 |
$90.97 |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
1,647 |
891 |
$89.22 |
| 99153 |
Mod sedat endo service >5yrs |
1,384 |
1,347 |
$88.99 |
| 80175 |
|
104 |
82 |
$88.62 |
| 82365 |
|
201 |
174 |
$87.86 |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
824 |
762 |
$83.88 |
| 90723 |
|
87 |
87 |
$82.03 |
| 88309 |
|
42 |
41 |
$78.24 |
| 80177 |
|
90 |
79 |
$77.41 |
| 43273 |
|
43 |
39 |
$73.37 |
| 83516 |
|
17 |
14 |
$70.26 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
16,266 |
14,337 |
$68.88 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
830 |
709 |
$65.30 |
| 87116 |
|
170 |
156 |
$64.80 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
6,668 |
4,641 |
$64.01 |
| 82378 |
|
72 |
63 |
$59.88 |
| C9290 |
Injection, bupivacaine liposome, 1 mg |
792 |
754 |
$58.88 |
| J7070 |
Infusion, d5w, 1000 cc |
420 |
290 |
$58.80 |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
1,717 |
1,267 |
$57.03 |
| 90632 |
|
852 |
816 |
$55.06 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
4,716 |
3,817 |
$50.18 |
| 82565 |
|
50 |
41 |
$49.65 |
| 87484 |
|
38 |
25 |
$49.12 |
| 86663 |
|
15 |
12 |
$46.53 |
| 87420 |
|
1,214 |
1,180 |
$45.60 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
335 |
323 |
$45.49 |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
800 |
725 |
$44.44 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
195 |
153 |
$43.45 |
| J2274 |
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg |
587 |
574 |
$41.50 |
| 89051 |
|
508 |
468 |
$40.78 |
| J1940 |
Injection, furosemide, up to 20 mg |
2,675 |
1,656 |
$40.70 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
892 |
392 |
$37.86 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
893 |
393 |
$37.86 |
| G8989 |
Self care functional limitation, discharge status, at discharge from therapy or to end reporting |
887 |
389 |
$37.86 |
| 87400 |
|
192 |
183 |
$37.80 |
| 77002 |
|
171 |
157 |
$37.36 |
| 88331 |
|
410 |
397 |
$36.80 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
917 |
837 |
$34.42 |
| 84155 |
|
48 |
38 |
$33.76 |
| 97804 |
|
153 |
148 |
$32.30 |
| Q9961 |
High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml |
266 |
249 |
$30.68 |
| J1836 |
Injection, metronidazole, 10 mg |
566 |
467 |
$27.14 |
| 82272 |
|
409 |
387 |
$26.64 |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
1,394 |
1,172 |
$26.35 |
| 82009 |
|
678 |
597 |
$26.19 |
| 82150 |
|
15 |
12 |
$25.92 |
| 86308 |
|
228 |
204 |
$25.90 |
| 83883 |
|
12 |
12 |
$23.20 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
1,275 |
1,038 |
$23.04 |
| 82247 |
|
13 |
12 |
$20.52 |
| J9267 |
Injection, paclitaxel, 1 mg |
563 |
309 |
$19.83 |
| 82044 |
|
353 |
338 |
$17.61 |
| 82962 |
|
170 |
63 |
$16.73 |
| 36416 |
|
14,808 |
12,170 |
$16.38 |
| 85014 |
|
16 |
12 |
$12.80 |
| 87207 |
|
12 |
12 |
$12.26 |
| 80306 |
|
194 |
132 |
$11.22 |
| J1805 |
Injection, esmolol hydrochloride, 10 mg |
55 |
39 |
$9.74 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
1,114 |
876 |
$9.54 |
| 89050 |
|
13 |
12 |
$9.44 |
| 85384 |
|
103 |
100 |
$8.68 |
| 82040 |
|
15 |
13 |
$7.90 |
| J0736 |
Injection, clindamycin phosphate, 300 mg |
20 |
15 |
$7.41 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
1,460 |
1,277 |
$6.46 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
4,657 |
3,128 |
$6.03 |
| 84157 |
|
13 |
12 |
$4.25 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
365 |
298 |
$3.76 |
| J3260 |
Injection, tobramycin sulfate, up to 80 mg |
194 |
178 |
$2.50 |
| C1760 |
Closure device, vascular (implantable/insertable) |
370 |
358 |
$2.00 |
| 93321 |
|
782 |
634 |
$1.52 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
2,564 |
1,811 |
$0.36 |
| J2305 |
Injection, nitroglycerin, 5 mg |
129 |
109 |
$0.05 |
| 90697 |
|
2,632 |
2,212 |
$0.00 |
| 90698 |
|
3,960 |
3,704 |
$0.00 |
| 90717 |
|
59 |
58 |
$0.00 |
| 91317 |
|
56 |
56 |
$0.00 |
| 76820 |
|
1,095 |
359 |
$0.00 |
| C1759 |
Catheter, intracardiac echocardiography |
65 |
59 |
$0.00 |
| 92556 |
|
100 |
97 |
$0.00 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
1,250 |
551 |
$0.00 |
| 90474 |
|
3,815 |
3,461 |
$0.00 |
| 95886 |
|
275 |
202 |
$0.00 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
157 |
119 |
$0.00 |
| 90696 |
|
1,550 |
1,305 |
$0.00 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
1,000 |
800 |
$0.00 |
| 64494 |
|
388 |
161 |
$0.00 |
| 76377 |
|
85 |
79 |
$0.00 |
| 90647 |
|
309 |
292 |
$0.00 |
| 77001 |
|
131 |
128 |
$0.00 |
| 90660 |
|
29 |
25 |
$0.00 |
| C1781 |
Mesh (implantable) |
229 |
212 |
$0.00 |
| J8501 |
Aprepitant, oral, 5 mg |
449 |
425 |
$0.00 |
| 93320 |
|
306 |
250 |
$0.00 |
| 90381 |
|
121 |
116 |
$0.00 |
| 96368 |
|
780 |
593 |
$0.00 |
| 91307 |
|
505 |
468 |
$0.00 |
| 91315 |
|
45 |
45 |
$0.00 |
| C1766 |
Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away |
95 |
87 |
$0.00 |
| 11045 |
|
109 |
62 |
$0.00 |
| J2372 |
Injection, phenylephrine hydrochloride (biorphen), 20 micrograms |
86 |
30 |
$0.00 |
| C1893 |
Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away |
38 |
35 |
$0.00 |
| C1889 |
Implantable/insertable device, not otherwise classified |
55 |
53 |
$0.00 |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
26 |
25 |
$0.00 |
| 88185 |
|
70 |
58 |
$0.00 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
158 |
125 |
$0.00 |
| 91319 |
|
55 |
34 |
$0.00 |
| Q2036 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) |
27 |
27 |
$0.00 |
| 97010 |
|
585 |
189 |
$0.00 |
| 91305 |
|
627 |
602 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
20 |
13 |
$0.00 |
| 73120 |
|
20 |
12 |
$0.00 |
| G8998 |
Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting |
14 |
13 |
$0.00 |
| C1892 |
Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away |
12 |
12 |
$0.00 |
| A4627 |
Spacer, bag or reservoir, with or without mask, for use with metered dose inhaler |
44 |
39 |
$0.00 |
| 99174 |
|
66 |
61 |
$0.00 |
| 2000F |
|
28 |
25 |
$0.00 |
| 91303 |
|
32 |
32 |
$0.00 |
| 91318 |
|
105 |
63 |
$0.00 |
| 95885 |
|
82 |
46 |
$0.00 |
| J3411 |
Injection, thiamine hcl, 100 mg |
23 |
13 |
$0.00 |
| C1733 |
Catheter, electrophysiology, diagnostic/ablation, other than 3d or vector mapping, other than cool-tip |
15 |
13 |
$0.00 |
| 88311 |
|
13 |
13 |
$0.00 |
| J0456 |
Injection, azithromycin, 500 mg |
20 |
13 |
$0.00 |
| J2358 |
Injection, olanzapine, long-acting, 1 mg |
16 |
13 |
$0.00 |
| 64636 |
|
159 |
90 |
$0.00 |
| 90700 |
|
1,691 |
1,479 |
$0.00 |
| 95874 |
|
359 |
253 |
$0.00 |
| 90633 |
|
5,161 |
4,645 |
$0.00 |
| 17003 |
|
67 |
51 |
$0.00 |
| J0744 |
Injection, ciprofloxacin for intravenous infusion, 200 mg |
61 |
53 |
$0.00 |
| 78434 |
|
193 |
170 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
1,274 |
560 |
$0.00 |
| 90671 |
|
1,775 |
1,539 |
$0.00 |
| 90707 |
|
2,908 |
2,620 |
$0.00 |
| 97799 |
|
1,306 |
460 |
$0.00 |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
61 |
52 |
$0.00 |
| 91321 |
|
1,502 |
1,227 |
$0.00 |
| J0688 |
Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg |
104 |
94 |
$0.00 |
| J1953 |
Injection, levetiracetam, 10 mg |
30 |
24 |
$0.00 |
| 90713 |
|
1,005 |
911 |
$0.00 |
| G0500 |
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) |
251 |
246 |
$0.00 |
| Q2038 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) |
154 |
153 |
$0.00 |
| J0670 |
Injection, mepivacaine hydrochloride, per 10 ml |
36 |
28 |
$0.00 |
| J3489 |
Injection, zoledronic acid, 1 mg |
628 |
565 |
$0.00 |
| J0692 |
Injection, cefepime hydrochloride, 500 mg |
100 |
50 |
$0.00 |
| 64999 |
|
43 |
43 |
$0.00 |
| 96159 |
|
106 |
79 |
$0.00 |
| J0290 |
Injection, ampicillin sodium, 500 mg |
455 |
309 |
$0.00 |
| 76999 |
|
12 |
12 |
$0.00 |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
283 |
182 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
1,269 |
559 |
$0.00 |
| 90648 |
|
1,003 |
862 |
$0.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
864 |
607 |
$0.00 |
| 64643 |
|
381 |
296 |
$0.00 |
| J9190 |
Injection, fluorouracil, 500 mg |
274 |
152 |
$0.00 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
373 |
138 |
$0.00 |
| 90714 |
|
126 |
126 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
706 |
463 |
$0.00 |
| 91300 |
|
1,027 |
976 |
$0.00 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
349 |
266 |
$0.00 |
| 91312 |
|
694 |
683 |
$0.00 |
| J2401 |
Injection, chloroprocaine hydrochloride, per 1 mg |
42 |
15 |
$0.00 |
| C1874 |
Stent, coated/covered, with delivery system |
155 |
152 |
$0.00 |
| 91308 |
|
283 |
278 |
$0.00 |
| 80348 |
|
138 |
83 |
$0.00 |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
39 |
24 |
$0.00 |
| 90685 |
|
238 |
229 |
$0.00 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
14 |
14 |
$0.00 |
| J2004 |
Injection, lidocaine hcl with epinephrine, 1 mg |
307 |
291 |
$0.00 |
| Q0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg |
13 |
12 |
$0.00 |
| G2212 |
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) |
56 |
54 |
$0.00 |
| 92504 |
|
43 |
34 |
$0.00 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
15 |
13 |
$0.00 |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
14 |
13 |
$0.00 |
| J0153 |
Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) |
12 |
12 |
$0.00 |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
90 |
50 |
$0.00 |
| 85049 |
|
12 |
12 |
$0.00 |
| 96113 |
|
18 |
12 |
$0.00 |
| T1013 |
Sign language or oral interpretive services, per 15 minutes |
14 |
14 |
$0.00 |
| 64634 |
|
19 |
12 |
$0.00 |
| 90687 |
|
14 |
13 |
$0.00 |
| 88312 |
|
19 |
16 |
$0.00 |
| 80326 |
|
16 |
14 |
$0.00 |
| C2625 |
Stent, non-coronary, temporary, with delivery system |
18 |
13 |
$0.00 |